Relay Therapeutics

We look forward to reporting new RLY-2608 data this Monday, September 9, and will discuss them on a webcast at 8:00AM ET. Find full details here. https://lnkd.in/ePa4Sck8

With drug discovery innovations like #AI, we have the potential to create novel medicines that were not previously possible. Check out CBS News Saturday Morning's feature on AI in medicine for more on how our technology is driving the development of medicines that are making a difference for patients.

We were excited to partner with local nonprofit Community Servings again this summer. Community Servings serves medically tailored, nutritious, made-from-scratch meals to chronically and critically ill individuals and their families across New England. #FoodHeals

Come as you are at Relay Tx. Thanks to our Relay Resource Group, PaRTi, we celebrated #Pride this month with our favorite traditions: Pride trivia, drag bingo and our BAGLY, Inc. fundraiser. 🌈

Just published! We're excited to share our 2023 Corporate Responsibility report, which highlights our efforts to operate sustainably and responsibly. This year's report includes updates on our commitment to our patients, people, environment, community and governance. Check it out on our website. https://lnkd.in/gCxCKp_w

#ICYMI: Last week, we disclosed 3 new pre-clinical pipeline programs in #geneticdisease and solid tumors at our New Program & Platform Event. For full details on these programs and how the Dynamo™ platform led to these discoveries, access the webcast recording at the link below. https://lnkd.in/g79n8BnA

(9/9) We are focused on integrating industry-leading tools into our world-class Dynamo™ platform to continue rapidly growing and evolving. This morning’s New Program & Platform event underscored the potential for our pipeline programs to help many patients in need. Learn more about the new programs we announced earlier today here. https://lnkd.in/eFccCmAw

(8/9) By the end of 2025, we expect all 3 of these new programs to have entered the clinic. If so, this would total 11 development candidates, 7 Investigational New Drug Applications and 7 programs to have entered the clinic in the first decade of Relay Therapeutics’ history. The power of our Dynamo™ platform will continue to drive the next wave of Relay Tx’s growth and innovation in drug discovery.

(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.

(6/9) We are excited to disclose our second genetic disease program: Fabry disease. In #Fabrydisease, which effects approximately 8,000 people in the U.S., harmful levels of Gb3 accumulate in blood cells and tissues throughout the body, due to insufficient αGal enzyme activity, which can lead to a range of symptoms, including potentially life-threatening ones such as kidney failure, heart failure and stroke.     We have created the first non-inhibitory chaperone, which is designed to stabilize the αGal protein without inhibiting its activity, thus enabling greater Gb3 clearance across organs. We expect this program to enter the clinic in the second half of 2025.